Last reviewed · How we verify
NCT03874871
Function Preserving Gastrectomy for T1/2 Gastric Cancer Patients
trial testing Function preserving gastrectomy in Gastric Cancer in 300 participants. Status unknown.
1 March 2022
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 20 March 2019 |
| Primary completion | 1 March 2022 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Function preserving gastrectomy
- Standard gastrectomy
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- Gastrostomy — all drugs for Gastrostomy →
Sponsor
Peking University
Who can join
18 and older, any sex, with Gastric Cancer or Gastrostomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The real world based multi-cohorts study aims to evaluate the safety and effectiveness of function preserving gastrectomy including pylorus-preserving distal gastrectomy, proximal gastrectomy and wedge gastrectomy for T1 and T2 gastric cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current clinical trials on gastric cancer surgery in China.
Zhang S, Hu RH, Cui XM, Song C, et al · · 2024 · PMID 39554743 · DOI 10.4251/wjgo.v16.i11.4369
Verify or expand the search:
- PubMed search for NCT03874871
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03874871 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 8 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03874871.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing